Biopharma Deal Benchmarks
Data-driven licensing deal term analysis across oncology, neurology, and all major modalities. Upfronts, milestones, royalties, and deal structures.
Try the CalculatorMarket Overviews
Comprehensive 2026 deal landscape analysis across oncology, neurology, immunology, and metabolic/obesity therapeutic areas.
Oncology Licensing Deal Benchmarks 2026
Comprehensive 2026 oncology licensing deal benchmarks across ADCs, CAR-T, bispecifics, and all clinical stages. Data-driven analysis of upfronts, milestones, and royalties.
Neurology & CNS Licensing Deal Benchmarks 2026
Comprehensive 2026 neurology and CNS licensing deal benchmarks. Alzheimer's, Parkinson's, pain, and psychiatric disorder deal terms analyzed.
Metabolic & Obesity Deal Benchmarks 2026
Comprehensive 2026 metabolic and obesity licensing deal benchmarks. GLP-1 agonists, dual incretins, oral peptides, and MASH deal terms analyzed from 35+ R&D partnerships.
Rare Disease Licensing Deal Benchmarks 2026
Rare disease licensing deals average $2.2B total value at Phase 2 with orphan drug designation. Benchmark upfronts, milestones, and royalties across gene therapy, ERT, and substrate reduction.
Hematology Licensing Deal Benchmarks 2026
Comprehensive 2026 hematology licensing benchmarks. CAR-T, bispecific antibody, and small molecule deal terms across lymphoma, leukemia, and myeloproliferative neoplasms.
Dermatology Licensing Deal Benchmarks 2026
Comprehensive 2026 dermatology licensing benchmarks. IL-17, IL-13, JAK inhibitor, and topical biologic deal terms across atopic dermatitis, psoriasis, and emerging indications.
Gastroenterology Licensing Deal Benchmarks 2026
Comprehensive 2026 gastroenterology licensing benchmarks. Anti-TL1A, IL-23, and S1P modulator deal terms across Crohn's disease, ulcerative colitis, and emerging GI indications.
Immunology & Autoimmune Deal Benchmarks 2026
Immunology licensing deals average $3.0B total value at Phase 2. Benchmark autoimmune deal terms for lupus, JAK inhibitors, and biologics.
Cardiovascular Deal Benchmarks 2026
Cardiovascular licensing deals average $2.4B total value at Phase 2. Benchmark CV deal terms for heart failure, PCSK9, and lipid therapies.
Infectious Disease Deal Benchmarks 2026
Infectious disease licensing deals average $1.9B total value at Phase 2. Benchmark antiviral, antibiotic, and vaccine deal terms.
Ophthalmology Deal Benchmarks 2026
Ophthalmology licensing deals average $2.5B total value at Phase 2. Benchmark gene therapy, anti-VEGF, and retinal deal terms.
ADC vs. Bispecific Antibody Deal Terms Comparison
Compare ADC vs bispecific antibody deal terms: ADC median upfront $393M vs bispecific $348M. Side-by-side benchmarks.
Phase 1 vs. Phase 2 Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms: Phase 1 upfront $90M vs Phase 2 $258M. Data-driven stage comparison.
Oncology vs. Neurology Licensing Deal Comparison
Compare oncology vs neurology deal terms: oncology upfront $258M vs neurology $423M. TA-specific benchmarks.
ADC vs Bispecific Antibody — Oncology Deal Terms Comparison
Compare adc vs bispecific antibody deal terms in oncology: ADC median upfront $411M vs Bispecific Antibody $348M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs Monoclonal Antibody — Oncology Deal Terms Comparison
Compare small molecule vs monoclonal antibody deal terms in oncology: Small Molecule median upfront $258M vs Monoclonal Antibody $266M. Side-by-side benchmarks from 2,500+ deals.
ADC vs CAR-T (Heme) — Oncology Deal Terms Comparison
Compare adc vs car-t (heme) deal terms in oncology: ADC median upfront $411M vs CAR-T (Heme) $309M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs ADC — Oncology Deal Terms Comparison
Compare small molecule vs adc deal terms in oncology: Small Molecule median upfront $258M vs ADC $411M. Side-by-side benchmarks from 2,500+ deals.
Bispecific Antibody vs CAR-T (Heme) — Oncology Deal Terms Comparison
Compare bispecific antibody vs car-t (heme) deal terms in oncology: Bispecific Antibody median upfront $348M vs CAR-T (Heme) $309M. Side-by-side benchmarks from 2,500+ deals.
Radiopharmaceutical vs ADC — Oncology Deal Terms Comparison
Compare radiopharmaceutical vs adc deal terms in oncology: Radiopharmaceutical median upfront $407M vs ADC $411M. Side-by-side benchmarks from 2,500+ deals.
PROTAC vs Small Molecule — Oncology Deal Terms Comparison
Compare protac vs small molecule deal terms in oncology: PROTAC median upfront $348M vs Small Molecule $258M. Side-by-side benchmarks from 2,500+ deals.
Monoclonal Antibody vs Bispecific Antibody — Oncology Deal Terms Comparison
Compare monoclonal antibody vs bispecific antibody deal terms in oncology: Monoclonal Antibody median upfront $266M vs Bispecific Antibody $348M. Side-by-side benchmarks from 2,500+ deals.
Gene Therapy vs CAR-T (Solid Tumor) — Oncology Deal Terms Comparison
Compare gene therapy vs car-t (solid tumor) deal terms in oncology: Gene Therapy median upfront $253M vs CAR-T (Solid Tumor) $356M. Side-by-side benchmarks from 2,500+ deals.
RNAi / siRNA vs ASO — Oncology Deal Terms Comparison
Compare rnai / sirna vs aso deal terms in oncology: RNAi / siRNA median upfront $297M vs ASO $297M. Side-by-side benchmarks from 2,500+ deals.
Therapeutic Vaccine vs Monoclonal Antibody — Oncology Deal Terms Comparison
Compare therapeutic vaccine vs monoclonal antibody deal terms in oncology: Therapeutic Vaccine median upfront $297M vs Monoclonal Antibody $266M. Side-by-side benchmarks from 2,500+ deals.
Molecular Glue vs PROTAC — Oncology Deal Terms Comparison
Compare molecular glue vs protac deal terms in oncology: Molecular Glue median upfront $361M vs PROTAC $348M. Side-by-side benchmarks from 2,500+ deals.
ADC vs Radiopharmaceutical — Oncology Deal Terms Comparison
Compare adc vs radiopharmaceutical deal terms in oncology: ADC median upfront $411M vs Radiopharmaceutical $407M. Side-by-side benchmarks from 2,500+ deals.
CAR-T (Heme) vs CAR-T (Solid Tumor) — Oncology Deal Terms Comparison
Compare car-t (heme) vs car-t (solid tumor) deal terms in oncology: CAR-T (Heme) median upfront $309M vs CAR-T (Solid Tumor) $356M. Side-by-side benchmarks from 2,500+ deals.
Monoclonal Antibody vs ADC — Oncology Deal Terms Comparison
Compare monoclonal antibody vs adc deal terms in oncology: Monoclonal Antibody median upfront $266M vs ADC $411M. Side-by-side benchmarks from 2,500+ deals.
Bispecific Antibody vs T-Cell Engager — Oncology Deal Terms Comparison
Compare bispecific antibody vs t-cell engager deal terms in oncology: Bispecific Antibody median upfront $348M vs T-Cell Engager $335M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs PROTAC — Oncology Deal Terms Comparison
Compare small molecule vs protac deal terms in oncology: Small Molecule median upfront $258M vs PROTAC $348M. Side-by-side benchmarks from 2,500+ deals.
Oncolytic Virus vs Therapeutic Vaccine — Oncology Deal Terms Comparison
Compare oncolytic virus vs therapeutic vaccine deal terms in oncology: Oncolytic Virus median upfront $280M vs Therapeutic Vaccine $297M. Side-by-side benchmarks from 2,500+ deals.
mRNA vs Therapeutic Vaccine — Oncology Deal Terms Comparison
Compare mrna vs therapeutic vaccine deal terms in oncology: mRNA median upfront $335M vs Therapeutic Vaccine $297M. Side-by-side benchmarks from 2,500+ deals.
Peptide vs Small Molecule — Oncology Deal Terms Comparison
Compare peptide vs small molecule deal terms in oncology: Peptide median upfront $271M vs Small Molecule $258M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs Monoclonal Antibody — Neurology Deal Terms Comparison
Compare small molecule vs monoclonal antibody deal terms in neurology: Small Molecule median upfront $343M vs Monoclonal Antibody $354M. Side-by-side benchmarks from 2,500+ deals.
ASO vs Gene Therapy — Neurology Deal Terms Comparison
Compare aso vs gene therapy deal terms in neurology: ASO median upfront $389M vs Gene Therapy $331M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs BBB Platform — Neurology Deal Terms Comparison
Compare small molecule vs bbb platform deal terms in neurology: Small Molecule median upfront $343M vs BBB Platform $558M. Side-by-side benchmarks from 2,500+ deals.
Monoclonal Antibody vs Gene Therapy — Neurology Deal Terms Comparison
Compare monoclonal antibody vs gene therapy deal terms in neurology: Monoclonal Antibody median upfront $354M vs Gene Therapy $331M. Side-by-side benchmarks from 2,500+ deals.
Psychedelic vs Small Molecule — Neurology Deal Terms Comparison
Compare psychedelic vs small molecule deal terms in neurology: Psychedelic median upfront $378M vs Small Molecule $343M. Side-by-side benchmarks from 2,500+ deals.
Ion Channel vs Small Molecule — Neurology Deal Terms Comparison
Compare ion channel vs small molecule deal terms in neurology: Ion Channel median upfront $378M vs Small Molecule $343M. Side-by-side benchmarks from 2,500+ deals.
Tau-Targeting vs Monoclonal Antibody — Neurology Deal Terms Comparison
Compare tau-targeting vs monoclonal antibody deal terms in neurology: Tau-Targeting median upfront $464M vs Monoclonal Antibody $354M. Side-by-side benchmarks from 2,500+ deals.
ASO vs RNAi / siRNA — Neurology Deal Terms Comparison
Compare aso vs rnai / sirna deal terms in neurology: ASO median upfront $389M vs RNAi / siRNA $395M. Side-by-side benchmarks from 2,500+ deals.
Stem Cell vs Gene Therapy — Neurology Deal Terms Comparison
Compare stem cell vs gene therapy deal terms in neurology: Stem Cell median upfront $395M vs Gene Therapy $331M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs ASO — Neurology Deal Terms Comparison
Compare small molecule vs aso deal terms in neurology: Small Molecule median upfront $343M vs ASO $389M. Side-by-side benchmarks from 2,500+ deals.
BBB Platform vs Gene Therapy — Neurology Deal Terms Comparison
Compare bbb platform vs gene therapy deal terms in neurology: BBB Platform median upfront $558M vs Gene Therapy $331M. Side-by-side benchmarks from 2,500+ deals.
Peptide vs Monoclonal Antibody — Neurology Deal Terms Comparison
Compare peptide vs monoclonal antibody deal terms in neurology: Peptide median upfront $361M vs Monoclonal Antibody $354M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs Psychedelic — Neurology Deal Terms Comparison
Compare small molecule vs psychedelic deal terms in neurology: Small Molecule median upfront $343M vs Psychedelic $378M. Side-by-side benchmarks from 2,500+ deals.
Monoclonal Antibody vs ASO — Neurology Deal Terms Comparison
Compare monoclonal antibody vs aso deal terms in neurology: Monoclonal Antibody median upfront $354M vs ASO $389M. Side-by-side benchmarks from 2,500+ deals.
Gene Therapy vs RNAi / siRNA — Neurology Deal Terms Comparison
Compare gene therapy vs rnai / sirna deal terms in neurology: Gene Therapy median upfront $331M vs RNAi / siRNA $395M. Side-by-side benchmarks from 2,500+ deals.
JAK Inhibitor vs TL1A Inhibitor — Immunology Deal Terms Comparison
Compare jak inhibitor vs tl1a inhibitor deal terms in immunology: JAK Inhibitor median upfront $513M vs TL1A Inhibitor $676M. Side-by-side benchmarks from 2,500+ deals.
Monoclonal Antibody vs Bispecific Antibody — Immunology Deal Terms Comparison
Compare monoclonal antibody vs bispecific antibody deal terms in immunology: Monoclonal Antibody median upfront $480M vs Bispecific Antibody $629M. Side-by-side benchmarks from 2,500+ deals.
CAR-T (Autoimmune) vs Monoclonal Antibody — Immunology Deal Terms Comparison
Compare car-t (autoimmune) vs monoclonal antibody deal terms in immunology: CAR-T (Autoimmune) median upfront $914M vs Monoclonal Antibody $480M. Side-by-side benchmarks from 2,500+ deals.
FcRn Antagonist vs Complement Inhibitor — Immunology Deal Terms Comparison
Compare fcrn antagonist vs complement inhibitor deal terms in immunology: FcRn Antagonist median upfront $583M vs Complement Inhibitor $560M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs Monoclonal Antibody — Immunology Deal Terms Comparison
Compare small molecule vs monoclonal antibody deal terms in immunology: Small Molecule median upfront $466M vs Monoclonal Antibody $480M. Side-by-side benchmarks from 2,500+ deals.
JAK Inhibitor vs Monoclonal Antibody — Immunology Deal Terms Comparison
Compare jak inhibitor vs monoclonal antibody deal terms in immunology: JAK Inhibitor median upfront $513M vs Monoclonal Antibody $480M. Side-by-side benchmarks from 2,500+ deals.
S1P Modulator vs JAK Inhibitor — Immunology Deal Terms Comparison
Compare s1p modulator vs jak inhibitor deal terms in immunology: S1P Modulator median upfront $536M vs JAK Inhibitor $513M. Side-by-side benchmarks from 2,500+ deals.
Oral Integrin vs TL1A Inhibitor — Immunology Deal Terms Comparison
Compare oral integrin vs tl1a inhibitor deal terms in immunology: Oral Integrin median upfront $629M vs TL1A Inhibitor $676M. Side-by-side benchmarks from 2,500+ deals.
CAR-T (Autoimmune) vs CAR-Treg — Immunology Deal Terms Comparison
Compare car-t (autoimmune) vs car-treg deal terms in immunology: CAR-T (Autoimmune) median upfront $914M vs CAR-Treg $767M. Side-by-side benchmarks from 2,500+ deals.
Bispecific Antibody vs FcRn Antagonist — Immunology Deal Terms Comparison
Compare bispecific antibody vs fcrn antagonist deal terms in immunology: Bispecific Antibody median upfront $629M vs FcRn Antagonist $583M. Side-by-side benchmarks from 2,500+ deals.
Monoclonal Antibody vs FcRn Antagonist — Immunology Deal Terms Comparison
Compare monoclonal antibody vs fcrn antagonist deal terms in immunology: Monoclonal Antibody median upfront $480M vs FcRn Antagonist $583M. Side-by-side benchmarks from 2,500+ deals.
Complement Inhibitor vs Monoclonal Antibody — Immunology Deal Terms Comparison
Compare complement inhibitor vs monoclonal antibody deal terms in immunology: Complement Inhibitor median upfront $560M vs Monoclonal Antibody $480M. Side-by-side benchmarks from 2,500+ deals.
Dual Antagonist vs Monoclonal Antibody — Immunology Deal Terms Comparison
Compare dual antagonist vs monoclonal antibody deal terms in immunology: Dual Antagonist median upfront $606M vs Monoclonal Antibody $480M. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs JAK Inhibitor — Immunology Deal Terms Comparison
Compare small molecule vs jak inhibitor deal terms in immunology: Small Molecule median upfront $466M vs JAK Inhibitor $513M. Side-by-side benchmarks from 2,500+ deals.
In Vivo CAR-T vs CAR-T (Autoimmune) — Immunology Deal Terms Comparison
Compare in vivo car-t vs car-t (autoimmune) deal terms in immunology: In Vivo CAR-T median upfront $652M vs CAR-T (Autoimmune) $914M. Side-by-side benchmarks from 2,500+ deals.
GLP-1 Agonist vs Dual Incretin — Metabolic Deal Terms Comparison
Compare glp-1 agonist vs dual incretin deal terms in metabolic: GLP-1 Agonist median upfront $935M vs Dual Incretin $1.2B. Side-by-side benchmarks from 2,500+ deals.
GLP-1 Agonist vs Oral Peptide — Metabolic Deal Terms Comparison
Compare glp-1 agonist vs oral peptide deal terms in metabolic: GLP-1 Agonist median upfront $935M vs Oral Peptide $1.4B. Side-by-side benchmarks from 2,500+ deals.
Dual Incretin vs Triple Incretin — Metabolic Deal Terms Comparison
Compare dual incretin vs triple incretin deal terms in metabolic: Dual Incretin median upfront $1.2B vs Triple Incretin $1.2B. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs GLP-1 Agonist — Metabolic Deal Terms Comparison
Compare small molecule vs glp-1 agonist deal terms in metabolic: Small Molecule median upfront $683M vs GLP-1 Agonist $935M. Side-by-side benchmarks from 2,500+ deals.
SGLT2 Inhibitor vs GLP-1 Agonist — Metabolic Deal Terms Comparison
Compare sglt2 inhibitor vs glp-1 agonist deal terms in metabolic: SGLT2 Inhibitor median upfront $751M vs GLP-1 Agonist $935M. Side-by-side benchmarks from 2,500+ deals.
Amylin Analog vs GLP-1 Agonist — Metabolic Deal Terms Comparison
Compare amylin analog vs glp-1 agonist deal terms in metabolic: Amylin Analog median upfront $996M vs GLP-1 Agonist $935M. Side-by-side benchmarks from 2,500+ deals.
Anti-Activin vs GLP-1 Agonist — Metabolic Deal Terms Comparison
Compare anti-activin vs glp-1 agonist deal terms in metabolic: Anti-Activin median upfront $1.0B vs GLP-1 Agonist $935M. Side-by-side benchmarks from 2,500+ deals.
Oral Peptide vs Dual Incretin — Metabolic Deal Terms Comparison
Compare oral peptide vs dual incretin deal terms in metabolic: Oral Peptide median upfront $1.4B vs Dual Incretin $1.2B. Side-by-side benchmarks from 2,500+ deals.
Small Molecule vs Dual Incretin — Metabolic Deal Terms Comparison
Compare small molecule vs dual incretin deal terms in metabolic: Small Molecule median upfront $683M vs Dual Incretin $1.2B. Side-by-side benchmarks from 2,500+ deals.
Monoclonal Antibody vs GLP-1 Agonist — Metabolic Deal Terms Comparison
Compare monoclonal antibody vs glp-1 agonist deal terms in metabolic: Monoclonal Antibody median upfront $703M vs GLP-1 Agonist $935M. Side-by-side benchmarks from 2,500+ deals.
Microbiome vs GLP-1 Agonist — Metabolic Deal Terms Comparison
Compare microbiome vs glp-1 agonist deal terms in metabolic: Microbiome median upfront $533M vs GLP-1 Agonist $935M. Side-by-side benchmarks from 2,500+ deals.
Gene Therapy vs Small Molecule — Metabolic Deal Terms Comparison
Compare gene therapy vs small molecule deal terms in metabolic: Gene Therapy median upfront $669M vs Small Molecule $683M. Side-by-side benchmarks from 2,500+ deals.
Triple Incretin vs Oral Peptide — Metabolic Deal Terms Comparison
Compare triple incretin vs oral peptide deal terms in metabolic: Triple Incretin median upfront $1.2B vs Oral Peptide $1.4B. Side-by-side benchmarks from 2,500+ deals.
Gene Therapy vs ASO — Rare Disease Deal Terms Comparison
Compare gene therapy vs aso deal terms in rare disease: Gene Therapy median upfront $285M vs ASO $456M. Side-by-side benchmarks from 2,500+ deals.
Gene Therapy vs Small Molecule — Rare Disease Deal Terms Comparison
Compare gene therapy vs small molecule deal terms in rare disease: Gene Therapy median upfront $285M vs Small Molecule $446M. Side-by-side benchmarks from 2,500+ deals.
Monoclonal Antibody vs Small Molecule — Rare Disease Deal Terms Comparison
Compare monoclonal antibody vs small molecule deal terms in rare disease: Monoclonal Antibody median upfront $409M vs Small Molecule $446M. Side-by-side benchmarks from 2,500+ deals.
Cell Therapy vs Gene Therapy — Rare Disease Deal Terms Comparison
Compare cell therapy vs gene therapy deal terms in rare disease: Cell Therapy median upfront $456M vs Gene Therapy $285M. Side-by-side benchmarks from 2,500+ deals.
RNAi / siRNA vs ASO — Rare Disease Deal Terms Comparison
Compare rnai / sirna vs aso deal terms in rare disease: RNAi / siRNA median upfront $456M vs ASO $456M. Side-by-side benchmarks from 2,500+ deals.
Gene Therapy vs Cell Therapy — Rare Disease Deal Terms Comparison
Compare gene therapy vs cell therapy deal terms in rare disease: Gene Therapy median upfront $285M vs Cell Therapy $456M. Side-by-side benchmarks from 2,500+ deals.
Peptide vs Small Molecule — Rare Disease Deal Terms Comparison
Compare peptide vs small molecule deal terms in rare disease: Peptide median upfront $416M vs Small Molecule $446M. Side-by-side benchmarks from 2,500+ deals.
Preclinical vs Phase 1 — Oncology Deal Valuation Comparison
Compare Preclinical vs Phase 1 deal terms in oncology: Phase 1 commands a 75% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Oncology Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in oncology: Phase 2 commands a 86% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Oncology Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in oncology: Phase 3 commands a 92% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 3 vs Approved — Oncology Deal Valuation Comparison
Compare Phase 3 vs Approved deal terms in oncology: Approved commands a 80% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 2 — Oncology Deal Valuation Comparison
Compare Preclinical vs Phase 2 deal terms in oncology: Phase 2 commands a 225% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 1 — Neurology Deal Valuation Comparison
Compare Preclinical vs Phase 1 deal terms in neurology: Phase 1 commands a 46% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Neurology Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in neurology: Phase 2 commands a 87% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Neurology Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in neurology: Phase 3 commands a 33% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 3 vs Approved — Neurology Deal Valuation Comparison
Compare Phase 3 vs Approved deal terms in neurology: Approved commands a 75% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 2 — Neurology Deal Valuation Comparison
Compare Preclinical vs Phase 2 deal terms in neurology: Phase 2 commands a 173% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 1 — Immunology Deal Valuation Comparison
Compare Preclinical vs Phase 1 deal terms in immunology: Phase 1 commands a 46% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Immunology Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in immunology: Phase 2 commands a 89% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Immunology Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in immunology: Phase 3 commands a 22% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 3 vs Approved — Immunology Deal Valuation Comparison
Compare Phase 3 vs Approved deal terms in immunology: Approved commands a 150% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 2 — Immunology Deal Valuation Comparison
Compare Preclinical vs Phase 2 deal terms in immunology: Phase 2 commands a 177% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 1 — Metabolic Deal Valuation Comparison
Compare Preclinical vs Phase 1 deal terms in metabolic: Phase 1 commands a 83% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Metabolic Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in metabolic: Phase 2 commands a 55% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Metabolic Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in metabolic: Phase 3 commands a 65% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 3 vs Approved — Metabolic Deal Valuation Comparison
Compare Phase 3 vs Approved deal terms in metabolic: Approved commands a 96% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 2 — Metabolic Deal Valuation Comparison
Compare Preclinical vs Phase 2 deal terms in metabolic: Phase 2 commands a 183% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 1 — Rare Disease Deal Valuation Comparison
Compare Preclinical vs Phase 1 deal terms in rare disease: Phase 1 commands a 70% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Rare Disease Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in rare disease: Phase 2 commands a 86% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Rare Disease Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in rare disease: Phase 3 commands a 114% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 3 vs Approved — Rare Disease Deal Valuation Comparison
Compare Phase 3 vs Approved deal terms in rare disease: Approved commands a 87% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Preclinical vs Phase 2 — Rare Disease Deal Valuation Comparison
Compare Preclinical vs Phase 2 deal terms in rare disease: Phase 2 commands a 215% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Hematology Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in hematology: Phase 2 commands a 85% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Hematology Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in hematology: Phase 3 commands a 129% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Dermatology Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in dermatology: Phase 2 commands a 129% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Dermatology Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in dermatology: Phase 3 commands a 119% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Gastroenterology Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in gastroenterology: Phase 2 commands a 122% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Gastroenterology Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in gastroenterology: Phase 3 commands a 110% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Cardiovascular Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in cardiovascular: Phase 2 commands a 125% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Cardiovascular Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in cardiovascular: Phase 3 commands a 78% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Infectious Disease Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in infectious disease: Phase 2 commands a 100% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Infectious Disease Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in infectious disease: Phase 3 commands a 79% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 1 vs Phase 2 — Ophthalmology Deal Valuation Comparison
Compare Phase 1 vs Phase 2 deal terms in ophthalmology: Phase 2 commands a 113% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Phase 2 vs Phase 3 — Ophthalmology Deal Valuation Comparison
Compare Phase 2 vs Phase 3 deal terms in ophthalmology: Phase 3 commands a 87% premium. Side-by-side upfronts, milestones, and royalty benchmarks.
Oncology vs Neurology — Deal Terms Comparison
Compare oncology vs neurology licensing deal terms: Oncology median upfront $258M vs Neurology $343M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Immunology — Deal Terms Comparison
Compare oncology vs immunology licensing deal terms: Oncology median upfront $258M vs Immunology $480M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Metabolic — Deal Terms Comparison
Compare oncology vs metabolic licensing deal terms: Oncology median upfront $258M vs Metabolic $935M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Hematology — Deal Terms Comparison
Compare oncology vs hematology licensing deal terms: Oncology median upfront $258M vs Hematology $604M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Rare Disease — Deal Terms Comparison
Compare oncology vs rare disease licensing deal terms: Oncology median upfront $258M vs Rare Disease $285M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Cardiovascular — Deal Terms Comparison
Compare oncology vs cardiovascular licensing deal terms: Oncology median upfront $258M vs Cardiovascular $606M. Side-by-side TA benchmarks from 2,500+ deals.
Neurology vs Immunology — Deal Terms Comparison
Compare neurology vs immunology licensing deal terms: Neurology median upfront $343M vs Immunology $480M. Side-by-side TA benchmarks from 2,500+ deals.
Neurology vs Metabolic — Deal Terms Comparison
Compare neurology vs metabolic licensing deal terms: Neurology median upfront $343M vs Metabolic $935M. Side-by-side TA benchmarks from 2,500+ deals.
Neurology vs Rare Disease — Deal Terms Comparison
Compare neurology vs rare disease licensing deal terms: Neurology median upfront $343M vs Rare Disease $285M. Side-by-side TA benchmarks from 2,500+ deals.
Neurology vs Dermatology — Deal Terms Comparison
Compare neurology vs dermatology licensing deal terms: Neurology median upfront $343M vs Dermatology $393M. Side-by-side TA benchmarks from 2,500+ deals.
Immunology vs Dermatology — Deal Terms Comparison
Compare immunology vs dermatology licensing deal terms: Immunology median upfront $480M vs Dermatology $393M. Side-by-side TA benchmarks from 2,500+ deals.
Immunology vs Gastroenterology — Deal Terms Comparison
Compare immunology vs gastroenterology licensing deal terms: Immunology median upfront $480M vs Gastroenterology $529M. Side-by-side TA benchmarks from 2,500+ deals.
Immunology vs Metabolic — Deal Terms Comparison
Compare immunology vs metabolic licensing deal terms: Immunology median upfront $480M vs Metabolic $935M. Side-by-side TA benchmarks from 2,500+ deals.
Immunology vs Rare Disease — Deal Terms Comparison
Compare immunology vs rare disease licensing deal terms: Immunology median upfront $480M vs Rare Disease $285M. Side-by-side TA benchmarks from 2,500+ deals.
Metabolic vs Cardiovascular — Deal Terms Comparison
Compare metabolic vs cardiovascular licensing deal terms: Metabolic median upfront $935M vs Cardiovascular $606M. Side-by-side TA benchmarks from 2,500+ deals.
Metabolic vs Rare Disease — Deal Terms Comparison
Compare metabolic vs rare disease licensing deal terms: Metabolic median upfront $935M vs Rare Disease $285M. Side-by-side TA benchmarks from 2,500+ deals.
Rare Disease vs Hematology — Deal Terms Comparison
Compare rare disease vs hematology licensing deal terms: Rare Disease median upfront $285M vs Hematology $604M. Side-by-side TA benchmarks from 2,500+ deals.
Rare Disease vs Ophthalmology — Deal Terms Comparison
Compare rare disease vs ophthalmology licensing deal terms: Rare Disease median upfront $285M vs Ophthalmology $768M. Side-by-side TA benchmarks from 2,500+ deals.
Hematology vs Immunology — Deal Terms Comparison
Compare hematology vs immunology licensing deal terms: Hematology median upfront $604M vs Immunology $480M. Side-by-side TA benchmarks from 2,500+ deals.
Dermatology vs Gastroenterology — Deal Terms Comparison
Compare dermatology vs gastroenterology licensing deal terms: Dermatology median upfront $393M vs Gastroenterology $529M. Side-by-side TA benchmarks from 2,500+ deals.
Cardiovascular vs Metabolic — Deal Terms Comparison
Compare cardiovascular vs metabolic licensing deal terms: Cardiovascular median upfront $606M vs Metabolic $935M. Side-by-side TA benchmarks from 2,500+ deals.
Infectious Disease vs Oncology — Deal Terms Comparison
Compare infectious disease vs oncology licensing deal terms: Infectious Disease median upfront $604M vs Oncology $258M. Side-by-side TA benchmarks from 2,500+ deals.
Ophthalmology vs Rare Disease — Deal Terms Comparison
Compare ophthalmology vs rare disease licensing deal terms: Ophthalmology median upfront $768M vs Rare Disease $285M. Side-by-side TA benchmarks from 2,500+ deals.
Hematology vs Oncology — Deal Terms Comparison
Compare hematology vs oncology licensing deal terms: Hematology median upfront $604M vs Oncology $258M. Side-by-side TA benchmarks from 2,500+ deals.
Gastroenterology vs Immunology — Deal Terms Comparison
Compare gastroenterology vs immunology licensing deal terms: Gastroenterology median upfront $529M vs Immunology $480M. Side-by-side TA benchmarks from 2,500+ deals.
Dermatology vs Immunology — Deal Terms Comparison
Compare dermatology vs immunology licensing deal terms: Dermatology median upfront $393M vs Immunology $480M. Side-by-side TA benchmarks from 2,500+ deals.
Neurology vs Cardiovascular — Deal Terms Comparison
Compare neurology vs cardiovascular licensing deal terms: Neurology median upfront $343M vs Cardiovascular $606M. Side-by-side TA benchmarks from 2,500+ deals.
Metabolic vs Gastroenterology — Deal Terms Comparison
Compare metabolic vs gastroenterology licensing deal terms: Metabolic median upfront $935M vs Gastroenterology $529M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Infectious Disease — Deal Terms Comparison
Compare oncology vs infectious disease licensing deal terms: Oncology median upfront $258M vs Infectious Disease $604M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Dermatology — Deal Terms Comparison
Compare oncology vs dermatology licensing deal terms: Oncology median upfront $258M vs Dermatology $393M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Gastroenterology — Deal Terms Comparison
Compare oncology vs gastroenterology licensing deal terms: Oncology median upfront $258M vs Gastroenterology $529M. Side-by-side TA benchmarks from 2,500+ deals.
Oncology vs Ophthalmology — Deal Terms Comparison
Compare oncology vs ophthalmology licensing deal terms: Oncology median upfront $258M vs Ophthalmology $768M. Side-by-side TA benchmarks from 2,500+ deals.
Neurology vs Hematology — Deal Terms Comparison
Compare neurology vs hematology licensing deal terms: Neurology median upfront $343M vs Hematology $604M. Side-by-side TA benchmarks from 2,500+ deals.
Immunology vs Ophthalmology — Deal Terms Comparison
Compare immunology vs ophthalmology licensing deal terms: Immunology median upfront $480M vs Ophthalmology $768M. Side-by-side TA benchmarks from 2,500+ deals.
Immunology vs Infectious Disease — Deal Terms Comparison
Compare immunology vs infectious disease licensing deal terms: Immunology median upfront $480M vs Infectious Disease $604M. Side-by-side TA benchmarks from 2,500+ deals.
Cardiovascular vs Infectious Disease — Deal Terms Comparison
Compare cardiovascular vs infectious disease licensing deal terms: Cardiovascular median upfront $606M vs Infectious Disease $604M. Side-by-side TA benchmarks from 2,500+ deals.
Metabolic vs Ophthalmology — Deal Terms Comparison
Compare metabolic vs ophthalmology licensing deal terms: Metabolic median upfront $935M vs Ophthalmology $768M. Side-by-side TA benchmarks from 2,500+ deals.
Rare Disease vs Dermatology — Deal Terms Comparison
Compare rare disease vs dermatology licensing deal terms: Rare Disease median upfront $285M vs Dermatology $393M. Side-by-side TA benchmarks from 2,500+ deals.
Hematology vs Dermatology — Deal Terms Comparison
Compare hematology vs dermatology licensing deal terms: Hematology median upfront $604M vs Dermatology $393M. Side-by-side TA benchmarks from 2,500+ deals.
Gastroenterology vs Metabolic — Deal Terms Comparison
Compare gastroenterology vs metabolic licensing deal terms: Gastroenterology median upfront $529M vs Metabolic $935M. Side-by-side TA benchmarks from 2,500+ deals.
Cardiovascular vs Hematology — Deal Terms Comparison
Compare cardiovascular vs hematology licensing deal terms: Cardiovascular median upfront $606M vs Hematology $604M. Side-by-side TA benchmarks from 2,500+ deals.
Immunology vs Cardiovascular — Deal Terms Comparison
Compare immunology vs cardiovascular licensing deal terms: Immunology median upfront $480M vs Cardiovascular $606M. Side-by-side TA benchmarks from 2,500+ deals.
Rare Disease vs Cardiovascular — Deal Terms Comparison
Compare rare disease vs cardiovascular licensing deal terms: Rare Disease median upfront $285M vs Cardiovascular $606M. Side-by-side TA benchmarks from 2,500+ deals.
Infectious Disease vs Neurology — Deal Terms Comparison
Compare infectious disease vs neurology licensing deal terms: Infectious Disease median upfront $604M vs Neurology $343M. Side-by-side TA benchmarks from 2,500+ deals.
Rare Disease vs Gastroenterology — Deal Terms Comparison
Compare rare disease vs gastroenterology licensing deal terms: Rare Disease median upfront $285M vs Gastroenterology $529M. Side-by-side TA benchmarks from 2,500+ deals.
Ophthalmology vs Neurology — Deal Terms Comparison
Compare ophthalmology vs neurology licensing deal terms: Ophthalmology median upfront $768M vs Neurology $343M. Side-by-side TA benchmarks from 2,500+ deals.
Dermatology vs Cardiovascular — Deal Terms Comparison
Compare dermatology vs cardiovascular licensing deal terms: Dermatology median upfront $393M vs Cardiovascular $606M. Side-by-side TA benchmarks from 2,500+ deals.
Infectious Disease vs Metabolic — Deal Terms Comparison
Compare infectious disease vs metabolic licensing deal terms: Infectious Disease median upfront $604M vs Metabolic $935M. Side-by-side TA benchmarks from 2,500+ deals.
Hematology vs Gastroenterology — Deal Terms Comparison
Compare hematology vs gastroenterology licensing deal terms: Hematology median upfront $604M vs Gastroenterology $529M. Side-by-side TA benchmarks from 2,500+ deals.
Ophthalmology vs Dermatology — Deal Terms Comparison
Compare ophthalmology vs dermatology licensing deal terms: Ophthalmology median upfront $768M vs Dermatology $393M. Side-by-side TA benchmarks from 2,500+ deals.
By Modality
Deal benchmarks segmented by drug modality — ADCs, CAR-T, bispecifics, gene therapy, and more.
ADC Licensing Deal Benchmarks
ADC licensing deals average $2.5B total value with $393M upfront at Phase 2. Explore benchmark deal terms for antibody-drug conjugates.
CAR-T Cell Therapy Deal Benchmarks
CAR-T licensing deals average $1.0B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for hematologic CAR-T cell therapies.
Bispecific Antibody Deal Benchmarks
Bispecific antibody licensing deals average $2.2B total value at Phase 2. Benchmark upfronts, milestones, and royalties for bispecific deals.
Radiopharmaceutical Deal Benchmarks
Radiopharmaceutical deals average $1.5B total value at Phase 1. Explore upfront payments, milestones, and royalty benchmarks for RPT licensing.
Gene Therapy & Gene Editing Deal Benchmarks
Gene therapy licensing deals average $864M total value at Phase 1. Benchmark upfronts, milestones, and royalty rates for gene therapy and gene editing deals.
Small Molecule Licensing Deal Benchmarks
Small molecule licensing deals average $1.6B total value at Phase 2. Comprehensive benchmarks for upfronts, milestones, and royalties.
GLP-1 Agonist Obesity Deal Benchmarks 2026
GLP-1 agonist obesity deals average $4.5B total value at Phase 2. Compare injectable vs oral GLP-1 deal terms, upfronts, milestones, and royalties.
Dual & Triple Incretin Deal Benchmarks 2026
Dual incretin (GLP-1/GIP) deals average $5.5B total value. Compare dual vs triple agonist deal terms and benchmarks.
Oral Peptide & Oral GLP-1 Deal Benchmarks 2026
Oral peptide obesity deals average $5.1B total value — 20-30% premium over injectables. Benchmark oral GLP-1 deal terms.
Gene Therapy Rare Disease Deal Benchmarks
Gene therapy rare disease deals average $1.2B total value at Phase 1. Benchmark upfronts, milestones, and royalties for orphan gene therapy licensing.
Enzyme Replacement Therapy Deal Benchmarks
ERT licensing deals average $2.3B total value at Phase 2. Benchmark deal terms for enzyme replacement therapies targeting Fabry, Gaucher, and Pompe disease.
CAR-T Hematology Deal Benchmarks
CAR-T hematology deals average $2.1B total value at Phase 1. Benchmark upfronts, milestones, and royalties for hematologic CAR-T cell therapy licensing.
Bispecific Antibody Hematology Deal Benchmarks
Bispecific antibody hematology deals average $3.6B total value at Phase 2. Benchmark deal terms for hematologic bispecific antibody licensing.
IL-17 Inhibitor Deal Benchmarks
IL-17 inhibitor licensing deals average $2.1B total value at Phase 2. Benchmark upfronts, milestones, and royalties for IL-17 pathway deals.
JAK Inhibitor Dermatology Deal Benchmarks
JAK inhibitor dermatology deals average $2.0B total value at Phase 2. Benchmark deal terms for JAK inhibitors in atopic dermatitis, alopecia areata, and vitiligo.
Anti-TL1A Deal Benchmarks
Anti-TL1A licensing deals average $3.3B total value at Phase 2. Benchmark deal terms for TL1A-targeting therapies in Crohn's disease and ulcerative colitis.
IL-23 GI Deal Benchmarks
IL-23 inhibitor GI deals average $3.0B total value at Phase 2. Benchmark deal terms for IL-23 targeting therapies in ulcerative colitis and Crohn's disease.
Checkpoint Inhibitor (PD-1/PD-L1) Deal Benchmarks
Checkpoint inhibitor licensing deals average $1.7B total value at Phase 2. Benchmark PD-1/PD-L1 IO deal terms, milestones, and royalties.
RNAi & siRNA Licensing Deal Benchmarks
RNAi/siRNA licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for RNA interference therapeutics.
PROTAC & Targeted Protein Degrader Deal Benchmarks
PROTAC/degrader licensing deals average $1.0B total value at Phase 1. Benchmark upfronts, milestones, and royalties for targeted protein degradation deals.
mRNA Therapeutics Deal Benchmarks
mRNA therapeutics licensing deals average $2.5B total value at Phase 2. Benchmark upfronts, milestones, and royalties for mRNA platform deals.
Monoclonal Antibody (mAb) Licensing Deal Benchmarks
Monoclonal antibody licensing deals average $2.5B total value at Phase 2. Benchmark upfronts, milestones, and royalties for mAb deals.
Cell Therapy Deal Benchmarks (Beyond CAR-T)
Non-CAR-T cell therapy deals average $1.0B total value at Phase 1. Benchmark upfronts, milestones, and royalties for TIL, NK cell, and iPSC-derived therapies.
Precision Oncology & Biomarker-Driven Deal Benchmarks
Biomarker-selected oncology deals average $1.9B total value at Phase 2. Benchmark upfronts, milestones, and royalties for precision medicine deals.
Obesity & Weight Loss Drug Deal Benchmarks 2026
Obesity/weight loss drug deals average $7.5B total value at Phase 3. Benchmark upfronts, milestones, and royalties for GLP-1 agonist licensing.
Autoimmune Biologics Deal Benchmarks
Autoimmune biologics licensing deals average $3.0B total value at Phase 2. Benchmark upfronts, milestones, and royalties for autoimmune biologic deals.
Rare Disease Gene Therapy Deal Benchmarks 2026
Rare disease gene therapy deals average $1.2B total value at Phase 1 in 2026. Updated benchmarks for orphan gene therapy upfronts, milestones, and royalties.
Approved Drug Licensing & Out-Licensing Deal Benchmarks
Approved drug licensing deals average $5.7B total value. Benchmark upfronts, milestones, and royalties for marketed product out-licensing deals.
Small Molecule Deal Benchmarks in Oncology
Comprehensive small molecule licensing and acquisition deal benchmarks for oncology. Median upfront $258M, total deal value $1.6B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Oncology
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for oncology. Median upfront $266M, total deal value $1.7B, and royalty rates from 2,500+ verified deals.
ADC (Antibody-Drug Conjugate) Deal Benchmarks in Oncology
Comprehensive adc (antibody-drug conjugate) licensing and acquisition deal benchmarks for oncology. Median upfront $411M, total deal value $2.6B, and royalty rates from 2,500+ verified deals.
Bispecific Antibody Deal Benchmarks in Oncology
Comprehensive bispecific antibody licensing and acquisition deal benchmarks for oncology. Median upfront $348M, total deal value $2.2B, and royalty rates from 2,500+ verified deals.
CAR-T (Hematologic) Deal Benchmarks in Oncology
Comprehensive car-t (hematologic) licensing and acquisition deal benchmarks for oncology. Median upfront $309M, total deal value $2.0B, and royalty rates from 2,500+ verified deals.
CAR-T (Solid Tumor) Deal Benchmarks in Oncology
Comprehensive car-t (solid tumor) licensing and acquisition deal benchmarks for oncology. Median upfront $356M, total deal value $2.3B, and royalty rates from 2,500+ verified deals.
Gene Therapy Deal Benchmarks in Oncology
Comprehensive gene therapy licensing and acquisition deal benchmarks for oncology. Median upfront $253M, total deal value $1.6B, and royalty rates from 2,500+ verified deals.
Radiopharmaceutical Deal Benchmarks in Oncology
Comprehensive radiopharmaceutical licensing and acquisition deal benchmarks for oncology. Median upfront $407M, total deal value $2.6B, and royalty rates from 2,500+ verified deals.
PROTAC Degrader Deal Benchmarks in Oncology
Comprehensive protac degrader licensing and acquisition deal benchmarks for oncology. Median upfront $348M, total deal value $2.2B, and royalty rates from 2,500+ verified deals.
Molecular Glue Deal Benchmarks in Oncology
Comprehensive molecular glue licensing and acquisition deal benchmarks for oncology. Median upfront $361M, total deal value $2.3B, and royalty rates from 2,500+ verified deals.
Therapeutic Vaccine Deal Benchmarks in Oncology
Comprehensive therapeutic vaccine licensing and acquisition deal benchmarks for oncology. Median upfront $297M, total deal value $1.9B, and royalty rates from 2,500+ verified deals.
Oncolytic Virus Deal Benchmarks in Oncology
Comprehensive oncolytic virus licensing and acquisition deal benchmarks for oncology. Median upfront $280M, total deal value $1.8B, and royalty rates from 2,500+ verified deals.
T-Cell Engager Deal Benchmarks in Oncology
Comprehensive t-cell engager licensing and acquisition deal benchmarks for oncology. Median upfront $335M, total deal value $2.1B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Oncology
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for oncology. Median upfront $271M, total deal value $1.7B, and royalty rates from 2,500+ verified deals.
RNAi / siRNA Deal Benchmarks in Oncology
Comprehensive rnai / sirna licensing and acquisition deal benchmarks for oncology. Median upfront $297M, total deal value $1.9B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Neurology
Comprehensive small molecule licensing and acquisition deal benchmarks for neurology. Median upfront $343M, total deal value $3.0B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Neurology
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for neurology. Median upfront $354M, total deal value $3.1B, and royalty rates from 2,500+ verified deals.
Gene Therapy Deal Benchmarks in Neurology
Comprehensive gene therapy licensing and acquisition deal benchmarks for neurology. Median upfront $331M, total deal value $3.0B, and royalty rates from 2,500+ verified deals.
Antisense Oligonucleotide (ASO) Deal Benchmarks in Neurology
Comprehensive antisense oligonucleotide (aso) licensing and acquisition deal benchmarks for neurology. Median upfront $389M, total deal value $3.5B, and royalty rates from 2,500+ verified deals.
BBB Platform Deal Benchmarks in Neurology
Comprehensive bbb platform licensing and acquisition deal benchmarks for neurology. Median upfront $558M, total deal value $5.0B, and royalty rates from 2,500+ verified deals.
Psychedelic-Derived Deal Benchmarks in Neurology
Comprehensive psychedelic-derived licensing and acquisition deal benchmarks for neurology. Median upfront $378M, total deal value $3.3B, and royalty rates from 2,500+ verified deals.
Ion Channel Modulator Deal Benchmarks in Neurology
Comprehensive ion channel modulator licensing and acquisition deal benchmarks for neurology. Median upfront $378M, total deal value $3.3B, and royalty rates from 2,500+ verified deals.
Tau-Targeting Deal Benchmarks in Neurology
Comprehensive tau-targeting licensing and acquisition deal benchmarks for neurology. Median upfront $464M, total deal value $4.1B, and royalty rates from 2,500+ verified deals.
Stem Cell Therapy Deal Benchmarks in Neurology
Comprehensive stem cell therapy licensing and acquisition deal benchmarks for neurology. Median upfront $395M, total deal value $3.5B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Neurology
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for neurology. Median upfront $361M, total deal value $3.2B, and royalty rates from 2,500+ verified deals.
RNAi / siRNA Deal Benchmarks in Neurology
Comprehensive rnai / sirna licensing and acquisition deal benchmarks for neurology. Median upfront $395M, total deal value $3.5B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Immunology & Autoimmune
Comprehensive small molecule licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $466M, total deal value $2.4B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Immunology & Autoimmune
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $480M, total deal value $2.5B, and royalty rates from 2,500+ verified deals.
Bispecific Antibody Deal Benchmarks in Immunology & Autoimmune
Comprehensive bispecific antibody licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $629M, total deal value $3.3B, and royalty rates from 2,500+ verified deals.
CAR-T (Autoimmune) Deal Benchmarks in Immunology & Autoimmune
Comprehensive car-t (autoimmune) licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $914M, total deal value $5.0B, and royalty rates from 2,500+ verified deals.
In Vivo CAR-T Deal Benchmarks in Immunology & Autoimmune
Comprehensive in vivo car-t licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $652M, total deal value $3.5B, and royalty rates from 2,500+ verified deals.
CAR-Treg Deal Benchmarks in Immunology & Autoimmune
Comprehensive car-treg licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $767M, total deal value $4.2B, and royalty rates from 2,500+ verified deals.
FcRn Antagonist Deal Benchmarks in Immunology & Autoimmune
Comprehensive fcrn antagonist licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $583M, total deal value $3.0B, and royalty rates from 2,500+ verified deals.
Complement Inhibitor Deal Benchmarks in Immunology & Autoimmune
Comprehensive complement inhibitor licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $560M, total deal value $2.9B, and royalty rates from 2,500+ verified deals.
JAK Inhibitor Deal Benchmarks in Immunology & Autoimmune
Comprehensive jak inhibitor licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $513M, total deal value $2.7B, and royalty rates from 2,500+ verified deals.
S1P Modulator Deal Benchmarks in Immunology & Autoimmune
Comprehensive s1p modulator licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $536M, total deal value $2.8B, and royalty rates from 2,500+ verified deals.
Oral Integrin Deal Benchmarks in Immunology & Autoimmune
Comprehensive oral integrin licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $629M, total deal value $3.3B, and royalty rates from 2,500+ verified deals.
Dual Antagonist Deal Benchmarks in Immunology & Autoimmune
Comprehensive dual antagonist licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $606M, total deal value $3.2B, and royalty rates from 2,500+ verified deals.
TL1A Inhibitor Deal Benchmarks in Immunology & Autoimmune
Comprehensive tl1a inhibitor licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $676M, total deal value $3.5B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Immunology & Autoimmune
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for immunology & autoimmune. Median upfront $490M, total deal value $2.6B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Metabolic & Obesity
Comprehensive small molecule licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $683M, total deal value $3.2B, and royalty rates from 2,500+ verified deals.
GLP-1 Agonist Deal Benchmarks in Metabolic & Obesity
Comprehensive glp-1 agonist licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $935M, total deal value $4.5B, and royalty rates from 2,500+ verified deals.
Dual Incretin Deal Benchmarks in Metabolic & Obesity
Comprehensive dual incretin licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $1.2B, total deal value $5.9B, and royalty rates from 2,500+ verified deals.
Triple Incretin Deal Benchmarks in Metabolic & Obesity
Comprehensive triple incretin licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $1.2B, total deal value $5.6B, and royalty rates from 2,500+ verified deals.
SGLT2 Inhibitor Deal Benchmarks in Metabolic & Obesity
Comprehensive sglt2 inhibitor licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $751M, total deal value $3.6B, and royalty rates from 2,500+ verified deals.
Amylin Analog Deal Benchmarks in Metabolic & Obesity
Comprehensive amylin analog licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $996M, total deal value $4.7B, and royalty rates from 2,500+ verified deals.
Oral Peptide Deal Benchmarks in Metabolic & Obesity
Comprehensive oral peptide licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $1.4B, total deal value $6.7B, and royalty rates from 2,500+ verified deals.
Anti-Activin Deal Benchmarks in Metabolic & Obesity
Comprehensive anti-activin licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $1.0B, total deal value $4.9B, and royalty rates from 2,500+ verified deals.
Microbiome-Based Deal Benchmarks in Metabolic & Obesity
Comprehensive microbiome-based licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $533M, total deal value $2.5B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Metabolic & Obesity
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $717M, total deal value $3.4B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Metabolic & Obesity
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $703M, total deal value $3.3B, and royalty rates from 2,500+ verified deals.
Gene Therapy Deal Benchmarks in Metabolic & Obesity
Comprehensive gene therapy licensing and acquisition deal benchmarks for metabolic & obesity. Median upfront $669M, total deal value $3.2B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Cardiovascular
Comprehensive small molecule licensing and acquisition deal benchmarks for cardiovascular. Median upfront $606M, total deal value $3.0B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Cardiovascular
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for cardiovascular. Median upfront $624M, total deal value $3.1B, and royalty rates from 2,500+ verified deals.
Myosin Inhibitor Deal Benchmarks in Cardiovascular
Comprehensive myosin inhibitor licensing and acquisition deal benchmarks for cardiovascular. Median upfront $788M, total deal value $4.0B, and royalty rates from 2,500+ verified deals.
Novel Anticoagulant Deal Benchmarks in Cardiovascular
Comprehensive novel anticoagulant licensing and acquisition deal benchmarks for cardiovascular. Median upfront $727M, total deal value $3.7B, and royalty rates from 2,500+ verified deals.
RNA Cardiovascular Deal Benchmarks in Cardiovascular
Comprehensive rna cardiovascular licensing and acquisition deal benchmarks for cardiovascular. Median upfront $757M, total deal value $3.8B, and royalty rates from 2,500+ verified deals.
PCSK9-Targeting Deal Benchmarks in Cardiovascular
Comprehensive pcsk9-targeting licensing and acquisition deal benchmarks for cardiovascular. Median upfront $697M, total deal value $3.5B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Cardiovascular
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for cardiovascular. Median upfront $636M, total deal value $3.2B, and royalty rates from 2,500+ verified deals.
Gene Therapy Deal Benchmarks in Cardiovascular
Comprehensive gene therapy licensing and acquisition deal benchmarks for cardiovascular. Median upfront $594M, total deal value $3.0B, and royalty rates from 2,500+ verified deals.
RNAi / siRNA Deal Benchmarks in Cardiovascular
Comprehensive rnai / sirna licensing and acquisition deal benchmarks for cardiovascular. Median upfront $697M, total deal value $3.5B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Infectious Disease
Comprehensive small molecule licensing and acquisition deal benchmarks for infectious disease. Median upfront $604M, total deal value $2.3B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Infectious Disease
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for infectious disease. Median upfront $622M, total deal value $2.4B, and royalty rates from 2,500+ verified deals.
Antiviral Deal Benchmarks in Infectious Disease
Comprehensive antiviral licensing and acquisition deal benchmarks for infectious disease. Median upfront $664M, total deal value $2.5B, and royalty rates from 2,500+ verified deals.
Novel Antibiotic Deal Benchmarks in Infectious Disease
Comprehensive novel antibiotic licensing and acquisition deal benchmarks for infectious disease. Median upfront $695M, total deal value $2.7B, and royalty rates from 2,500+ verified deals.
Preventive Vaccine Deal Benchmarks in Infectious Disease
Comprehensive preventive vaccine licensing and acquisition deal benchmarks for infectious disease. Median upfront $725M, total deal value $2.8B, and royalty rates from 2,500+ verified deals.
Phage Therapy Deal Benchmarks in Infectious Disease
Comprehensive phage therapy licensing and acquisition deal benchmarks for infectious disease. Median upfront $513M, total deal value $2.0B, and royalty rates from 2,500+ verified deals.
mRNA Therapeutic Deal Benchmarks in Infectious Disease
Comprehensive mrna therapeutic licensing and acquisition deal benchmarks for infectious disease. Median upfront $785M, total deal value $3.0B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Infectious Disease
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for infectious disease. Median upfront $634M, total deal value $2.4B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Ophthalmology
Comprehensive small molecule licensing and acquisition deal benchmarks for ophthalmology. Median upfront $607M, total deal value $2.9B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Ophthalmology
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for ophthalmology. Median upfront $625M, total deal value $2.9B, and royalty rates from 2,500+ verified deals.
Anti-VEGF Deal Benchmarks in Ophthalmology
Comprehensive anti-vegf licensing and acquisition deal benchmarks for ophthalmology. Median upfront $768M, total deal value $3.6B, and royalty rates from 2,500+ verified deals.
Gene Therapy (Ocular) Deal Benchmarks in Ophthalmology
Comprehensive gene therapy (ocular) licensing and acquisition deal benchmarks for ophthalmology. Median upfront $820M, total deal value $3.9B, and royalty rates from 2,500+ verified deals.
Intravitreal Deal Benchmarks in Ophthalmology
Comprehensive intravitreal licensing and acquisition deal benchmarks for ophthalmology. Median upfront $717M, total deal value $3.4B, and royalty rates from 2,500+ verified deals.
Topical Ophthalmic Deal Benchmarks in Ophthalmology
Comprehensive topical ophthalmic licensing and acquisition deal benchmarks for ophthalmology. Median upfront $491M, total deal value $2.3B, and royalty rates from 2,500+ verified deals.
RNAi / siRNA Deal Benchmarks in Ophthalmology
Comprehensive rnai / sirna licensing and acquisition deal benchmarks for ophthalmology. Median upfront $698M, total deal value $3.3B, and royalty rates from 2,500+ verified deals.
Gene Therapy Deal Benchmarks in Rare Disease
Comprehensive gene therapy licensing and acquisition deal benchmarks for rare disease. Median upfront $285M, total deal value $1.6B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Rare Disease
Comprehensive small molecule licensing and acquisition deal benchmarks for rare disease. Median upfront $446M, total deal value $2.4B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Rare Disease
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for rare disease. Median upfront $409M, total deal value $2.2B, and royalty rates from 2,500+ verified deals.
Antisense Oligonucleotide (ASO) Deal Benchmarks in Rare Disease
Comprehensive antisense oligonucleotide (aso) licensing and acquisition deal benchmarks for rare disease. Median upfront $456M, total deal value $2.5B, and royalty rates from 2,500+ verified deals.
RNAi / siRNA Deal Benchmarks in Rare Disease
Comprehensive rnai / sirna licensing and acquisition deal benchmarks for rare disease. Median upfront $456M, total deal value $2.5B, and royalty rates from 2,500+ verified deals.
Cell Therapy Deal Benchmarks in Rare Disease
Comprehensive cell therapy licensing and acquisition deal benchmarks for rare disease. Median upfront $456M, total deal value $2.5B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Rare Disease
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for rare disease. Median upfront $416M, total deal value $2.2B, and royalty rates from 2,500+ verified deals.
Oligonucleotide Deal Benchmarks in Rare Disease
Comprehensive oligonucleotide licensing and acquisition deal benchmarks for rare disease. Median upfront $468M, total deal value $2.5B, and royalty rates from 2,500+ verified deals.
CAR-T (Hematologic) Deal Benchmarks in Hematology
Comprehensive car-t (hematologic) licensing and acquisition deal benchmarks for hematology. Median upfront $751M, total deal value $3.8B, and royalty rates from 2,500+ verified deals.
Bispecific Antibody Deal Benchmarks in Hematology
Comprehensive bispecific antibody licensing and acquisition deal benchmarks for hematology. Median upfront $871M, total deal value $4.3B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Hematology
Comprehensive small molecule licensing and acquisition deal benchmarks for hematology. Median upfront $604M, total deal value $3.0B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Hematology
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for hematology. Median upfront $622M, total deal value $3.1B, and royalty rates from 2,500+ verified deals.
Gene Therapy Deal Benchmarks in Hematology
Comprehensive gene therapy licensing and acquisition deal benchmarks for hematology. Median upfront $592M, total deal value $2.9B, and royalty rates from 2,500+ verified deals.
Cell Therapy Deal Benchmarks in Hematology
Comprehensive cell therapy licensing and acquisition deal benchmarks for hematology. Median upfront $695M, total deal value $3.4B, and royalty rates from 2,500+ verified deals.
RNAi / siRNA Deal Benchmarks in Hematology
Comprehensive rnai / sirna licensing and acquisition deal benchmarks for hematology. Median upfront $695M, total deal value $3.4B, and royalty rates from 2,500+ verified deals.
Antisense Oligonucleotide (ASO) Deal Benchmarks in Hematology
Comprehensive antisense oligonucleotide (aso) licensing and acquisition deal benchmarks for hematology. Median upfront $695M, total deal value $3.4B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Dermatology
Comprehensive small molecule licensing and acquisition deal benchmarks for dermatology. Median upfront $393M, total deal value $2.1B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Dermatology
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for dermatology. Median upfront $405M, total deal value $2.2B, and royalty rates from 2,500+ verified deals.
JAK Inhibitor Deal Benchmarks in Dermatology
Comprehensive jak inhibitor licensing and acquisition deal benchmarks for dermatology. Median upfront $433M, total deal value $2.3B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Dermatology
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for dermatology. Median upfront $413M, total deal value $2.2B, and royalty rates from 2,500+ verified deals.
Topical Ophthalmic Deal Benchmarks in Dermatology
Comprehensive topical ophthalmic licensing and acquisition deal benchmarks for dermatology. Median upfront $383M, total deal value $2.0B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Gastroenterology
Comprehensive small molecule licensing and acquisition deal benchmarks for gastroenterology. Median upfront $514M, total deal value $2.6B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Gastroenterology
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for gastroenterology. Median upfront $529M, total deal value $2.7B, and royalty rates from 2,500+ verified deals.
Oral Integrin Deal Benchmarks in Gastroenterology
Comprehensive oral integrin licensing and acquisition deal benchmarks for gastroenterology. Median upfront $693M, total deal value $3.5B, and royalty rates from 2,500+ verified deals.
JAK Inhibitor Deal Benchmarks in Gastroenterology
Comprehensive jak inhibitor licensing and acquisition deal benchmarks for gastroenterology. Median upfront $565M, total deal value $2.9B, and royalty rates from 2,500+ verified deals.
S1P Modulator Deal Benchmarks in Gastroenterology
Comprehensive s1p modulator licensing and acquisition deal benchmarks for gastroenterology. Median upfront $586M, total deal value $3.0B, and royalty rates from 2,500+ verified deals.
TL1A Inhibitor Deal Benchmarks in Gastroenterology
Comprehensive tl1a inhibitor licensing and acquisition deal benchmarks for gastroenterology. Median upfront $745M, total deal value $3.8B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Gastroenterology
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for gastroenterology. Median upfront $539M, total deal value $2.7B, and royalty rates from 2,500+ verified deals.
Microbiome-Based Deal Benchmarks in Gastroenterology
Comprehensive microbiome-based licensing and acquisition deal benchmarks for gastroenterology. Median upfront $401M, total deal value $2.0B, and royalty rates from 2,500+ verified deals.
Small Molecule Deal Benchmarks in Women's Health
Comprehensive small molecule licensing and acquisition deal benchmarks for women's health. Median upfront $326M, total deal value $1.8B, and royalty rates from 2,500+ verified deals.
Monoclonal Antibody Deal Benchmarks in Women's Health
Comprehensive monoclonal antibody licensing and acquisition deal benchmarks for women's health. Median upfront $336M, total deal value $1.8B, and royalty rates from 2,500+ verified deals.
Peptide Therapeutic Deal Benchmarks in Women's Health
Comprehensive peptide therapeutic licensing and acquisition deal benchmarks for women's health. Median upfront $342M, total deal value $1.9B, and royalty rates from 2,500+ verified deals.
Gene Therapy Deal Benchmarks in Women's Health
Comprehensive gene therapy licensing and acquisition deal benchmarks for women's health. Median upfront $319M, total deal value $1.8B, and royalty rates from 2,500+ verified deals.
By Indication
Deal benchmarks for specific disease indications — NSCLC, breast cancer, myeloma, and Alzheimer's.
Lung Cancer (NSCLC) Licensing Deal Benchmarks
NSCLC licensing deals average $1.6B total value at Phase 2. Benchmark deal terms for non-small cell lung cancer licensing agreements.
Breast Cancer (TNBC) Licensing Deal Benchmarks
TNBC licensing deals average $2.5B total value at Phase 2. Benchmark upfronts, milestones, and royalties for triple-negative breast cancer deals.
Alzheimer's Disease Licensing Deal Benchmarks
Alzheimer's licensing deals average $3.5B total value at Phase 2. Benchmark deal terms for Alzheimer's disease-modifying and symptomatic therapies.
Multiple Myeloma Licensing Deal Benchmarks
Multiple myeloma licensing deals average $2.4B total value at Phase 2. Benchmark upfronts, milestones, and royalties for myeloma deals.
NASH/MASH Deal Benchmarks 2026
NASH/MASH licensing deals average $3.1B total value. Benchmark deal terms for steatohepatitis therapies following resmetirom approval.
Parkinson's Disease Licensing Deal Benchmarks
Parkinson's disease licensing deals average $3.1B total value at Phase 2. Benchmark PD deal terms, milestones, and royalties.
Lung Cancer (NSCLC) — Deal Benchmarks & Valuation
Lung Cancer (NSCLC) licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for lung cancer (nsclc) transactions.
Lung Cancer (SCLC) — Deal Benchmarks & Valuation
Lung Cancer (SCLC) licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for lung cancer (sclc) transactions.
Breast Cancer (HER2+) — Deal Benchmarks & Valuation
Breast Cancer (HER2+) licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for breast cancer (her2+) transactions.
Breast Cancer (TNBC) — Deal Benchmarks & Valuation
Breast Cancer (TNBC) licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for breast cancer (tnbc) transactions.
Breast Cancer (HR+) — Deal Benchmarks & Valuation
Breast Cancer (HR+) licensing deals average $1.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for breast cancer (hr+) transactions.
Colorectal Cancer — Deal Benchmarks & Valuation
Colorectal Cancer licensing deals average $2.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for colorectal cancer transactions.
Pancreatic Cancer — Deal Benchmarks & Valuation
Pancreatic Cancer licensing deals average $1.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for pancreatic cancer transactions.
Melanoma — Deal Benchmarks & Valuation
Melanoma licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for melanoma transactions.
Prostate Cancer (mCRPC) — Deal Benchmarks & Valuation
Prostate Cancer (mCRPC) licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for prostate cancer (mcrpc) transactions.
Ovarian Cancer — Deal Benchmarks & Valuation
Ovarian Cancer licensing deals average $2.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for ovarian cancer transactions.
Gastric / GEJ Cancer — Deal Benchmarks & Valuation
Gastric / GEJ Cancer licensing deals average $2.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for gastric / gej cancer transactions.
Liver Cancer (HCC) — Deal Benchmarks & Valuation
Liver Cancer (HCC) licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for liver cancer (hcc) transactions.
Renal Cell Carcinoma (RCC) — Deal Benchmarks & Valuation
Renal Cell Carcinoma (RCC) licensing deals average $1.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for renal cell carcinoma (rcc) transactions.
Glioblastoma (GBM) — Deal Benchmarks & Valuation
Glioblastoma (GBM) licensing deals average $1.4B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for glioblastoma (gbm) transactions.
Bladder Cancer — Deal Benchmarks & Valuation
Bladder Cancer licensing deals average $2.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for bladder cancer transactions.
Head & Neck Cancer — Deal Benchmarks & Valuation
Head & Neck Cancer licensing deals average $1.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for head & neck cancer transactions.
Cholangiocarcinoma — Deal Benchmarks & Valuation
Cholangiocarcinoma licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for cholangiocarcinoma transactions.
Mesothelioma — Deal Benchmarks & Valuation
Mesothelioma licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for mesothelioma transactions.
Sarcoma — Deal Benchmarks & Valuation
Sarcoma licensing deals average $1.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for sarcoma transactions.
Endometrial Cancer — Deal Benchmarks & Valuation
Endometrial Cancer licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for endometrial cancer transactions.
Cervical Cancer — Deal Benchmarks & Valuation
Cervical Cancer licensing deals average $2.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for cervical cancer transactions.
Thyroid Cancer — Deal Benchmarks & Valuation
Thyroid Cancer licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for thyroid cancer transactions.
Esophageal Cancer — Deal Benchmarks & Valuation
Esophageal Cancer licensing deals average $1.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for esophageal cancer transactions.
Neuroendocrine Tumors (NET) — Deal Benchmarks & Valuation
Neuroendocrine Tumors (NET) licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for neuroendocrine tumors (net) transactions.
Uveal Melanoma — Deal Benchmarks & Valuation
Uveal Melanoma licensing deals average $1.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for uveal melanoma transactions.
Merkel Cell Carcinoma — Deal Benchmarks & Valuation
Merkel Cell Carcinoma licensing deals average $1.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for merkel cell carcinoma transactions.
Testicular Cancer — Deal Benchmarks & Valuation
Testicular Cancer licensing deals average $1.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for testicular cancer transactions.
Nasopharyngeal Carcinoma — Deal Benchmarks & Valuation
Nasopharyngeal Carcinoma licensing deals average $1.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for nasopharyngeal carcinoma transactions.
KRAS-Mutant Tumors — Deal Benchmarks & Valuation
KRAS-Mutant Tumors licensing deals average $1.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for kras-mutant tumors transactions.
HER2-Low Tumors — Deal Benchmarks & Valuation
HER2-Low Tumors licensing deals average $2.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for her2-low tumors transactions.
MSI-High / dMMR Tumors — Deal Benchmarks & Valuation
MSI-High / dMMR Tumors licensing deals average $1.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for msi-high / dmmr tumors transactions.
Acute Myeloid Leukemia (AML) — Deal Benchmarks & Valuation
Acute Myeloid Leukemia (AML) licensing deals average $2.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for acute myeloid leukemia (aml) transactions.
Acute Lymphoblastic Leukemia (ALL) — Deal Benchmarks & Valuation
Acute Lymphoblastic Leukemia (ALL) licensing deals average $1.0B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for acute lymphoblastic leukemia (all) transactions.
Chronic Lymphocytic Leukemia (CLL) — Deal Benchmarks & Valuation
Chronic Lymphocytic Leukemia (CLL) licensing deals average $1.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for chronic lymphocytic leukemia (cll) transactions.
Multiple Myeloma — Deal Benchmarks & Valuation
Multiple Myeloma licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for multiple myeloma transactions.
Diffuse Large B-Cell Lymphoma (DLBCL) — Deal Benchmarks & Valuation
Diffuse Large B-Cell Lymphoma (DLBCL) licensing deals average $1.0B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for diffuse large b-cell lymphoma (dlbcl) transactions.
Follicular Lymphoma — Deal Benchmarks & Valuation
Follicular Lymphoma licensing deals average $1.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for follicular lymphoma transactions.
Mantle Cell Lymphoma — Deal Benchmarks & Valuation
Mantle Cell Lymphoma licensing deals average $1.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for mantle cell lymphoma transactions.
Myelodysplastic Syndromes (MDS) — Deal Benchmarks & Valuation
Myelodysplastic Syndromes (MDS) licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for myelodysplastic syndromes (mds) transactions.
Hodgkin Lymphoma — Deal Benchmarks & Valuation
Hodgkin Lymphoma licensing deals average $2.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hodgkin lymphoma transactions.
Myeloproliferative Neoplasms (MPN) — Deal Benchmarks & Valuation
Myeloproliferative Neoplasms (MPN) licensing deals average $1.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for myeloproliferative neoplasms (mpn) transactions.
T-Cell Lymphoma — Deal Benchmarks & Valuation
T-Cell Lymphoma licensing deals average $1.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for t-cell lymphoma transactions.
Alzheimer's Disease — Deal Benchmarks & Valuation
Alzheimer's Disease licensing deals average $3.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for alzheimer's disease transactions.
ALS (Amyotrophic Lateral Sclerosis) — Deal Benchmarks & Valuation
ALS (Amyotrophic Lateral Sclerosis) licensing deals average $3.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for als (amyotrophic lateral sclerosis) transactions.
Huntington's Disease — Deal Benchmarks & Valuation
Huntington's Disease licensing deals average $2.1B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for huntington's disease transactions.
Multiple Sclerosis — Deal Benchmarks & Valuation
Multiple Sclerosis licensing deals average $2.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for multiple sclerosis transactions.
Epilepsy — Deal Benchmarks & Valuation
Epilepsy licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for epilepsy transactions.
Migraine — Deal Benchmarks & Valuation
Migraine licensing deals average $2.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for migraine transactions.
Schizophrenia — Deal Benchmarks & Valuation
Schizophrenia licensing deals average $2.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for schizophrenia transactions.
Depression / MDD — Deal Benchmarks & Valuation
Depression / MDD licensing deals average $2.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for depression / mdd transactions.
Chronic / Neuropathic Pain — Deal Benchmarks & Valuation
Chronic / Neuropathic Pain licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for chronic / neuropathic pain transactions.
Narcolepsy — Deal Benchmarks & Valuation
Narcolepsy licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for narcolepsy transactions.
Autism Spectrum Disorder — Deal Benchmarks & Valuation
Autism Spectrum Disorder licensing deals average $2.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for autism spectrum disorder transactions.
Rett Syndrome — Deal Benchmarks & Valuation
Rett Syndrome licensing deals average $1.7B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for rett syndrome transactions.
Spinal Muscular Atrophy (SMA) — Deal Benchmarks & Valuation
Spinal Muscular Atrophy (SMA) licensing deals average $1.8B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for spinal muscular atrophy (sma) transactions.
Angelman Syndrome — Deal Benchmarks & Valuation
Angelman Syndrome licensing deals average $1.8B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for angelman syndrome transactions.
Dravet Syndrome — Deal Benchmarks & Valuation
Dravet Syndrome licensing deals average $3.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for dravet syndrome transactions.
Addiction / Substance Use Disorders — Deal Benchmarks & Valuation
Addiction / Substance Use Disorders licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for addiction / substance use disorders transactions.
Bipolar Disorder — Deal Benchmarks & Valuation
Bipolar Disorder licensing deals average $2.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for bipolar disorder transactions.
PTSD — Deal Benchmarks & Valuation
PTSD licensing deals average $3.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for ptsd transactions.
OCD / Anxiety Disorders — Deal Benchmarks & Valuation
OCD / Anxiety Disorders licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for ocd / anxiety disorders transactions.
Traumatic Brain Injury — Deal Benchmarks & Valuation
Traumatic Brain Injury licensing deals average $2.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for traumatic brain injury transactions.
Duchenne Muscular Dystrophy (Neuro) — Deal Benchmarks & Valuation
Duchenne Muscular Dystrophy (Neuro) licensing deals average $1.8B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for duchenne muscular dystrophy (neuro) transactions.
Friedreich's Ataxia — Deal Benchmarks & Valuation
Friedreich's Ataxia licensing deals average $1.7B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for friedreich's ataxia transactions.
Frontotemporal Dementia (FTD) — Deal Benchmarks & Valuation
Frontotemporal Dementia (FTD) licensing deals average $1.6B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for frontotemporal dementia (ftd) transactions.
Lewy Body Dementia — Deal Benchmarks & Valuation
Lewy Body Dementia licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for lewy body dementia transactions.
Myotonic Dystrophy — Deal Benchmarks & Valuation
Myotonic Dystrophy licensing deals average $2.0B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for myotonic dystrophy transactions.
Movement Disorders / Tremor — Deal Benchmarks & Valuation
Movement Disorders / Tremor licensing deals average $2.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for movement disorders / tremor transactions.
ADHD — Deal Benchmarks & Valuation
ADHD licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for adhd transactions.
Insomnia — Deal Benchmarks & Valuation
Insomnia licensing deals average $2.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for insomnia transactions.
Rheumatoid Arthritis — Deal Benchmarks & Valuation
Rheumatoid Arthritis licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for rheumatoid arthritis transactions.
Systemic Lupus (SLE) — Deal Benchmarks & Valuation
Systemic Lupus (SLE) licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for systemic lupus (sle) transactions.
Lupus Nephritis — Deal Benchmarks & Valuation
Lupus Nephritis licensing deals average $3.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for lupus nephritis transactions.
Atopic Dermatitis (Immunology) — Deal Benchmarks & Valuation
Atopic Dermatitis (Immunology) licensing deals average $2.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for atopic dermatitis (immunology) transactions.
Psoriasis (Immunology) — Deal Benchmarks & Valuation
Psoriasis (Immunology) licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for psoriasis (immunology) transactions.
Ulcerative Colitis — Deal Benchmarks & Valuation
Ulcerative Colitis licensing deals average $4.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for ulcerative colitis transactions.
Crohn's Disease (Immunology) — Deal Benchmarks & Valuation
Crohn's Disease (Immunology) licensing deals average $4.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for crohn's disease (immunology) transactions.
Myasthenia Gravis — Deal Benchmarks & Valuation
Myasthenia Gravis licensing deals average $4.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for myasthenia gravis transactions.
IgA Nephropathy — Deal Benchmarks & Valuation
IgA Nephropathy licensing deals average $3.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for iga nephropathy transactions.
ANCA Vasculitis — Deal Benchmarks & Valuation
ANCA Vasculitis licensing deals average $3.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for anca vasculitis transactions.
Hidradenitis Suppurativa — Deal Benchmarks & Valuation
Hidradenitis Suppurativa licensing deals average $2.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hidradenitis suppurativa transactions.
Severe Asthma — Deal Benchmarks & Valuation
Severe Asthma licensing deals average $2.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for severe asthma transactions.
Eosinophilic Esophagitis (EoE) — Deal Benchmarks & Valuation
Eosinophilic Esophagitis (EoE) licensing deals average $3.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for eosinophilic esophagitis (eoe) transactions.
Graft-vs-Host Disease (GVHD) — Deal Benchmarks & Valuation
Graft-vs-Host Disease (GVHD) licensing deals average $3.5B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for graft-vs-host disease (gvhd) transactions.
CIDP — Deal Benchmarks & Valuation
CIDP licensing deals average $3.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for cidp transactions.
PNH — Deal Benchmarks & Valuation
PNH licensing deals average $4.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for pnh transactions.
Systemic Sclerosis — Deal Benchmarks & Valuation
Systemic Sclerosis licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for systemic sclerosis transactions.
Sjogren's Syndrome — Deal Benchmarks & Valuation
Sjogren's Syndrome licensing deals average $2.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for sjogren's syndrome transactions.
Idiopathic Pulmonary Fibrosis (IPF) — Deal Benchmarks & Valuation
Idiopathic Pulmonary Fibrosis (IPF) licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for idiopathic pulmonary fibrosis (ipf) transactions.
COPD (Immunology) — Deal Benchmarks & Valuation
COPD (Immunology) licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for copd (immunology) transactions.
Ankylosing Spondylitis — Deal Benchmarks & Valuation
Ankylosing Spondylitis licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for ankylosing spondylitis transactions.
Giant Cell Arteritis — Deal Benchmarks & Valuation
Giant Cell Arteritis licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for giant cell arteritis transactions.
Pemphigus — Deal Benchmarks & Valuation
Pemphigus licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for pemphigus transactions.
Immune Thrombocytopenia (ITP) — Deal Benchmarks & Valuation
Immune Thrombocytopenia (ITP) licensing deals average $2.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for immune thrombocytopenia (itp) transactions.
Vitiligo (Immunology) — Deal Benchmarks & Valuation
Vitiligo (Immunology) licensing deals average $2.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for vitiligo (immunology) transactions.
Multiple Sclerosis (Immunology) — Deal Benchmarks & Valuation
Multiple Sclerosis (Immunology) licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for multiple sclerosis (immunology) transactions.
Obesity — Deal Benchmarks & Valuation
Obesity licensing deals average $4.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for obesity transactions.
Type 2 Diabetes — Deal Benchmarks & Valuation
Type 2 Diabetes licensing deals average $4.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for type 2 diabetes transactions.
NASH / MASH — Deal Benchmarks & Valuation
NASH / MASH licensing deals average $3.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for nash / mash transactions.
Type 1 Diabetes — Deal Benchmarks & Valuation
Type 1 Diabetes licensing deals average $3.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for type 1 diabetes transactions.
Gout — Deal Benchmarks & Valuation
Gout licensing deals average $2.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for gout transactions.
Fabry Disease — Deal Benchmarks & Valuation
Fabry Disease licensing deals average $2.2B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for fabry disease transactions.
Gaucher Disease — Deal Benchmarks & Valuation
Gaucher Disease licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for gaucher disease transactions.
Pompe Disease — Deal Benchmarks & Valuation
Pompe Disease licensing deals average $2.0B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for pompe disease transactions.
Phenylketonuria (PKU) — Deal Benchmarks & Valuation
Phenylketonuria (PKU) licensing deals average $1.9B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for phenylketonuria (pku) transactions.
Metabolic Syndrome — Deal Benchmarks & Valuation
Metabolic Syndrome licensing deals average $4.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for metabolic syndrome transactions.
CKD (Metabolic) — Deal Benchmarks & Valuation
CKD (Metabolic) licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for ckd (metabolic) transactions.
Familial Hypercholesterolemia — Deal Benchmarks & Valuation
Familial Hypercholesterolemia licensing deals average $2.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for familial hypercholesterolemia transactions.
ATTR Amyloidosis — Deal Benchmarks & Valuation
ATTR Amyloidosis licensing deals average $3.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for attr amyloidosis transactions.
Heart Failure (HFrEF) — Deal Benchmarks & Valuation
Heart Failure (HFrEF) licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for heart failure (hfref) transactions.
Atrial Fibrillation — Deal Benchmarks & Valuation
Atrial Fibrillation licensing deals average $2.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for atrial fibrillation transactions.
Pulmonary Arterial Hypertension — Deal Benchmarks & Valuation
Pulmonary Arterial Hypertension licensing deals average $3.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for pulmonary arterial hypertension transactions.
Dyslipidemia — Deal Benchmarks & Valuation
Dyslipidemia licensing deals average $3.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for dyslipidemia transactions.
Cardiomyopathy — Deal Benchmarks & Valuation
Cardiomyopathy licensing deals average $4.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for cardiomyopathy transactions.
Hypertrophic Cardiomyopathy (HCM) — Deal Benchmarks & Valuation
Hypertrophic Cardiomyopathy (HCM) licensing deals average $4.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hypertrophic cardiomyopathy (hcm) transactions.
Coronary Artery Disease — Deal Benchmarks & Valuation
Coronary Artery Disease licensing deals average $2.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for coronary artery disease transactions.
Peripheral Artery Disease — Deal Benchmarks & Valuation
Peripheral Artery Disease licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for peripheral artery disease transactions.
Resistant Hypertension — Deal Benchmarks & Valuation
Resistant Hypertension licensing deals average $3.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for resistant hypertension transactions.
Stroke Prevention — Deal Benchmarks & Valuation
Stroke Prevention licensing deals average $3.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for stroke prevention transactions.
Heart Failure (HFpEF) — Deal Benchmarks & Valuation
Heart Failure (HFpEF) licensing deals average $3.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for heart failure (hfpef) transactions.
HIV / AIDS — Deal Benchmarks & Valuation
HIV / AIDS licensing deals average $2.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hiv / aids transactions.
Hepatitis B (HBV) — Deal Benchmarks & Valuation
Hepatitis B (HBV) licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hepatitis b (hbv) transactions.
RSV — Deal Benchmarks & Valuation
RSV licensing deals average $3.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for rsv transactions.
Influenza — Deal Benchmarks & Valuation
Influenza licensing deals average $3.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for influenza transactions.
Tuberculosis — Deal Benchmarks & Valuation
Tuberculosis licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for tuberculosis transactions.
AMR Bacterial Infections — Deal Benchmarks & Valuation
AMR Bacterial Infections licensing deals average $3.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for amr bacterial infections transactions.
Invasive Fungal Infections — Deal Benchmarks & Valuation
Invasive Fungal Infections licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for invasive fungal infections transactions.
COVID-19 — Deal Benchmarks & Valuation
COVID-19 licensing deals average $2.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for covid-19 transactions.
Hepatitis D (HDV) — Deal Benchmarks & Valuation
Hepatitis D (HDV) licensing deals average $2.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hepatitis d (hdv) transactions.
CMV Infection — Deal Benchmarks & Valuation
CMV Infection licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for cmv infection transactions.
C. difficile Infection — Deal Benchmarks & Valuation
C. difficile Infection licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for c. difficile infection transactions.
Wet AMD — Deal Benchmarks & Valuation
Wet AMD licensing deals average $3.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for wet amd transactions.
Dry AMD / Geographic Atrophy — Deal Benchmarks & Valuation
Dry AMD / Geographic Atrophy licensing deals average $3.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for dry amd / geographic atrophy transactions.
Diabetic Retinopathy — Deal Benchmarks & Valuation
Diabetic Retinopathy licensing deals average $3.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for diabetic retinopathy transactions.
Glaucoma — Deal Benchmarks & Valuation
Glaucoma licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for glaucoma transactions.
Dry Eye Disease — Deal Benchmarks & Valuation
Dry Eye Disease licensing deals average $2.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for dry eye disease transactions.
Retinitis Pigmentosa — Deal Benchmarks & Valuation
Retinitis Pigmentosa licensing deals average $2.3B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for retinitis pigmentosa transactions.
Diabetic Macular Edema — Deal Benchmarks & Valuation
Diabetic Macular Edema licensing deals average $3.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for diabetic macular edema transactions.
Myopia Progression — Deal Benchmarks & Valuation
Myopia Progression licensing deals average $2.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for myopia progression transactions.
Stargardt Disease — Deal Benchmarks & Valuation
Stargardt Disease licensing deals average $1.9B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for stargardt disease transactions.
Spinal Muscular Atrophy (SMA) — Deal Benchmarks & Valuation
Spinal Muscular Atrophy (SMA) licensing deals average $2.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for spinal muscular atrophy (sma) transactions.
Duchenne Muscular Dystrophy — Deal Benchmarks & Valuation
Duchenne Muscular Dystrophy licensing deals average $1.0B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for duchenne muscular dystrophy transactions.
Cystic Fibrosis — Deal Benchmarks & Valuation
Cystic Fibrosis licensing deals average $2.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for cystic fibrosis transactions.
Fabry Disease — Deal Benchmarks & Valuation
Fabry Disease licensing deals average $2.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for fabry disease transactions.
Gaucher Disease — Deal Benchmarks & Valuation
Gaucher Disease licensing deals average $2.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for gaucher disease transactions.
Pompe Disease — Deal Benchmarks & Valuation
Pompe Disease licensing deals average $2.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for pompe disease transactions.
Hemophilia A — Deal Benchmarks & Valuation
Hemophilia A licensing deals average $1.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hemophilia a transactions.
Hemophilia B — Deal Benchmarks & Valuation
Hemophilia B licensing deals average $1.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hemophilia b transactions.
Sickle Cell Disease — Deal Benchmarks & Valuation
Sickle Cell Disease licensing deals average $1.1B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for sickle cell disease transactions.
Huntington's Disease (Rare) — Deal Benchmarks & Valuation
Huntington's Disease (Rare) licensing deals average $1.3B total value at Phase 1. Benchmark upfront payments, milestones, and royalties for huntington's disease (rare) transactions.
Beta-Thalassemia — Deal Benchmarks & Valuation
Beta-Thalassemia licensing deals average $1.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for beta-thalassemia transactions.
Mucopolysaccharidosis (MPS) — Deal Benchmarks & Valuation
Mucopolysaccharidosis (MPS) licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for mucopolysaccharidosis (mps) transactions.
Niemann-Pick Type C — Deal Benchmarks & Valuation
Niemann-Pick Type C licensing deals average $2.2B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for niemann-pick type c transactions.
Fragile X Syndrome — Deal Benchmarks & Valuation
Fragile X Syndrome licensing deals average $2.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for fragile x syndrome transactions.
Follicular Lymphoma — Deal Benchmarks & Valuation
Follicular Lymphoma licensing deals average $3.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for follicular lymphoma transactions.
Myelofibrosis — Deal Benchmarks & Valuation
Myelofibrosis licensing deals average $3.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for myelofibrosis transactions.
Aplastic Anemia — Deal Benchmarks & Valuation
Aplastic Anemia licensing deals average $3.1B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for aplastic anemia transactions.
Polycythemia Vera — Deal Benchmarks & Valuation
Polycythemia Vera licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for polycythemia vera transactions.
Waldenstrom's Macroglobulinemia — Deal Benchmarks & Valuation
Waldenstrom's Macroglobulinemia licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for waldenstrom's macroglobulinemia transactions.
Mantle Cell Lymphoma (Heme) — Deal Benchmarks & Valuation
Mantle Cell Lymphoma (Heme) licensing deals average $2.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for mantle cell lymphoma (heme) transactions.
Hodgkin Lymphoma (Heme) — Deal Benchmarks & Valuation
Hodgkin Lymphoma (Heme) licensing deals average $2.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hodgkin lymphoma (heme) transactions.
Atopic Dermatitis — Deal Benchmarks & Valuation
Atopic Dermatitis licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for atopic dermatitis transactions.
Alopecia Areata — Deal Benchmarks & Valuation
Alopecia Areata licensing deals average $1.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for alopecia areata transactions.
Hidradenitis Suppurativa — Deal Benchmarks & Valuation
Hidradenitis Suppurativa licensing deals average $2.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for hidradenitis suppurativa transactions.
Chronic Urticaria — Deal Benchmarks & Valuation
Chronic Urticaria licensing deals average $2.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for chronic urticaria transactions.
Acne — Deal Benchmarks & Valuation
Acne licensing deals average $1.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for acne transactions.
Rosacea — Deal Benchmarks & Valuation
Rosacea licensing deals average $1.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for rosacea transactions.
Prurigo Nodularis — Deal Benchmarks & Valuation
Prurigo Nodularis licensing deals average $2.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for prurigo nodularis transactions.
Crohn's Disease — Deal Benchmarks & Valuation
Crohn's Disease licensing deals average $3.3B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for crohn's disease transactions.
Celiac Disease — Deal Benchmarks & Valuation
Celiac Disease licensing deals average $2.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for celiac disease transactions.
IBS-D — Deal Benchmarks & Valuation
IBS-D licensing deals average $1.9B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for ibs-d transactions.
Short Bowel Syndrome — Deal Benchmarks & Valuation
Short Bowel Syndrome licensing deals average $2.6B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for short bowel syndrome transactions.
Primary Biliary Cholangitis (PBC) — Deal Benchmarks & Valuation
Primary Biliary Cholangitis (PBC) licensing deals average $2.5B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for primary biliary cholangitis (pbc) transactions.
Microscopic Colitis — Deal Benchmarks & Valuation
Microscopic Colitis licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for microscopic colitis transactions.
Gastroparesis — Deal Benchmarks & Valuation
Gastroparesis licensing deals average $2.4B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for gastroparesis transactions.
NASH (GI) — Deal Benchmarks & Valuation
NASH (GI) licensing deals average $2.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for nash (gi) transactions.
Endometriosis — Deal Benchmarks & Valuation
Endometriosis licensing deals average $1.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for endometriosis transactions.
Uterine Fibroids — Deal Benchmarks & Valuation
Uterine Fibroids licensing deals average $1.7B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for uterine fibroids transactions.
PCOS — Deal Benchmarks & Valuation
PCOS licensing deals average $1.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for pcos transactions.
Menopause — Deal Benchmarks & Valuation
Menopause licensing deals average $1.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for menopause transactions.
Postpartum Depression — Deal Benchmarks & Valuation
Postpartum Depression licensing deals average $1.8B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for postpartum depression transactions.
Preeclampsia — Deal Benchmarks & Valuation
Preeclampsia licensing deals average $2.0B total value at Phase 2. Benchmark upfront payments, milestones, and royalties for preeclampsia transactions.
By Clinical Stage
Deal benchmarks across development stages — preclinical, Phase 2, and Phase 3 licensing terms.
Preclinical Licensing Deal Benchmarks
Preclinical licensing deals average $504M total value. Benchmark upfronts, milestones, and royalties for IND-enabling stage assets.
Phase 2 Licensing Deal Benchmarks
Phase 2 licensing deals average $1.6B total value. Comprehensive benchmarks for upfronts, milestones, and royalties at the proof-of-concept stage.
Phase 3 Licensing Deal Benchmarks
Phase 3 licensing deals average $3.1B total value with $721M upfront. Benchmark deal terms for pivotal-stage assets.
Preclinical Oncology Deal Benchmarks
Preclinical oncology licensing deal benchmarks: median upfront $32M, total deal value $504M, and royalty rates. Data from 2,500+ verified transactions.
Phase 1 Oncology Deal Benchmarks
Phase 1 oncology licensing deal benchmarks: median upfront $90M, total deal value $882M, and royalty rates. Data from 2,500+ verified transactions.
Phase 1/2 Oncology Deal Benchmarks
Phase 1/2 oncology licensing deal benchmarks: median upfront $163M, total deal value $1.3B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2 Oncology Deal Benchmarks
Phase 2 oncology licensing deal benchmarks: median upfront $258M, total deal value $1.6B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2/3 Oncology Deal Benchmarks
Phase 2/3 oncology licensing deal benchmarks: median upfront $470M, total deal value $2.4B, and royalty rates. Data from 2,500+ verified transactions.
Phase 3 Oncology Deal Benchmarks
Phase 3 oncology licensing deal benchmarks: median upfront $721M, total deal value $3.1B, and royalty rates. Data from 2,500+ verified transactions.
Approved Oncology Deal Benchmarks
Approved oncology licensing deal benchmarks: median upfront $2.1B, total deal value $5.7B, and royalty rates. Data from 2,500+ verified transactions.
Preclinical Neurology Deal Benchmarks
Preclinical neurology licensing deal benchmarks: median upfront $47M, total deal value $1.1B, and royalty rates. Data from 2,500+ verified transactions.
Phase 1 Neurology Deal Benchmarks
Phase 1 neurology licensing deal benchmarks: median upfront $112M, total deal value $1.6B, and royalty rates. Data from 2,500+ verified transactions.
Phase 1/2 Neurology Deal Benchmarks
Phase 1/2 neurology licensing deal benchmarks: median upfront $223M, total deal value $2.3B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2 Neurology Deal Benchmarks
Phase 2 neurology licensing deal benchmarks: median upfront $343M, total deal value $3.0B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2/3 Neurology Deal Benchmarks
Phase 2/3 neurology licensing deal benchmarks: median upfront $536M, total deal value $3.5B, and royalty rates. Data from 2,500+ verified transactions.
Phase 3 Neurology Deal Benchmarks
Phase 3 neurology licensing deal benchmarks: median upfront $770M, total deal value $4.1B, and royalty rates. Data from 2,500+ verified transactions.
Approved Neurology Deal Benchmarks
Approved neurology licensing deal benchmarks: median upfront $2.2B, total deal value $7.1B, and royalty rates. Data from 2,500+ verified transactions.
Preclinical Immunology & Autoimmune Deal Benchmarks
Preclinical immunology & autoimmune licensing deal benchmarks: median upfront $61M, total deal value $878M, and royalty rates. Data from 2,500+ verified transactions.
Phase 1 Immunology & Autoimmune Deal Benchmarks
Phase 1 immunology & autoimmune licensing deal benchmarks: median upfront $139M, total deal value $1.3B, and royalty rates. Data from 2,500+ verified transactions.
Phase 1/2 Immunology & Autoimmune Deal Benchmarks
Phase 1/2 immunology & autoimmune licensing deal benchmarks: median upfront $284M, total deal value $1.9B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2 Immunology & Autoimmune Deal Benchmarks
Phase 2 immunology & autoimmune licensing deal benchmarks: median upfront $466M, total deal value $2.4B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2/3 Immunology & Autoimmune Deal Benchmarks
Phase 2/3 immunology & autoimmune licensing deal benchmarks: median upfront $562M, total deal value $2.5B, and royalty rates. Data from 2,500+ verified transactions.
Phase 3 Immunology & Autoimmune Deal Benchmarks
Phase 3 immunology & autoimmune licensing deal benchmarks: median upfront $766M, total deal value $3.0B, and royalty rates. Data from 2,500+ verified transactions.
Approved Immunology & Autoimmune Deal Benchmarks
Approved immunology & autoimmune licensing deal benchmarks: median upfront $2.9B, total deal value $7.4B, and royalty rates. Data from 2,500+ verified transactions.
Preclinical Metabolic & Obesity Deal Benchmarks
Preclinical metabolic & obesity licensing deal benchmarks: median upfront $90M, total deal value $1.1B, and royalty rates. Data from 2,500+ verified transactions.
Phase 1 Metabolic & Obesity Deal Benchmarks
Phase 1 metabolic & obesity licensing deal benchmarks: median upfront $265M, total deal value $2.1B, and royalty rates. Data from 2,500+ verified transactions.
Phase 1/2 Metabolic & Obesity Deal Benchmarks
Phase 1/2 metabolic & obesity licensing deal benchmarks: median upfront $437M, total deal value $2.6B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2 Metabolic & Obesity Deal Benchmarks
Phase 2 metabolic & obesity licensing deal benchmarks: median upfront $683M, total deal value $3.2B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2/3 Metabolic & Obesity Deal Benchmarks
Phase 2/3 metabolic & obesity licensing deal benchmarks: median upfront $1.0B, total deal value $4.2B, and royalty rates. Data from 2,500+ verified transactions.
Phase 3 Metabolic & Obesity Deal Benchmarks
Phase 3 metabolic & obesity licensing deal benchmarks: median upfront $1.4B, total deal value $5.3B, and royalty rates. Data from 2,500+ verified transactions.
Approved Metabolic & Obesity Deal Benchmarks
Approved metabolic & obesity licensing deal benchmarks: median upfront $4.0B, total deal value $10.5B, and royalty rates. Data from 2,500+ verified transactions.
Preclinical Rare Disease Deal Benchmarks
Preclinical rare disease licensing deal benchmarks: median upfront $36M, total deal value $499M, and royalty rates. Data from 2,500+ verified transactions.
Phase 1 Rare Disease Deal Benchmarks
Phase 1 rare disease licensing deal benchmarks: median upfront $91M, total deal value $846M, and royalty rates. Data from 2,500+ verified transactions.
Phase 1/2 Rare Disease Deal Benchmarks
Phase 1/2 rare disease licensing deal benchmarks: median upfront $161M, total deal value $1.1B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2 Rare Disease Deal Benchmarks
Phase 2 rare disease licensing deal benchmarks: median upfront $285M, total deal value $1.6B, and royalty rates. Data from 2,500+ verified transactions.
Phase 2/3 Rare Disease Deal Benchmarks
Phase 2/3 rare disease licensing deal benchmarks: median upfront $543M, total deal value $2.4B, and royalty rates. Data from 2,500+ verified transactions.
Phase 3 Rare Disease Deal Benchmarks
Phase 3 rare disease licensing deal benchmarks: median upfront $971M, total deal value $3.4B, and royalty rates. Data from 2,500+ verified transactions.
Approved Rare Disease Deal Benchmarks
Approved rare disease licensing deal benchmarks: median upfront $2.6B, total deal value $6.3B, and royalty rates. Data from 2,500+ verified transactions.
Model Your Own Deal Terms
Use our calculator to customize inputs for your specific asset — phase, modality, indication, competitive position, and more — and get instant deal term estimates.
Start Calculating